Physician profile
Kyle A Carpenter
NPI 1912428475
$5,718.19
in general payments reported to CMS, 2019-2025
35 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $927 · 2023: $1,188 · 2024: $1,685 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,482.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,404.66 | 2021-2025 | |
| Novo Nordisk INC | $528.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $363.55 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $341.42 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $294.60 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Gilead Sciences, INC. | $256.35 | 2022-2024 | Epclusa |
| Qol Medical, LLC | $233.54 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $218.66 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Phathom Pharmaceuticals, INC. | $208.93 | 2024-2025 | Voquezna |
| Alkermes, INC. | $192.01 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $176.48 | 2023-2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $162.35 | 2022-2025 | Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $143.22 | 2022-2024 | |
| Corium, LLC | $140.00 | 2022 | |
| Verona Pharma, INC. | $115.38 | 2025 | Ohtuvayre |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $101.59 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $95.38 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $85.40 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $83.47 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $73.19 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.33 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.94 | 2022-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $56.27 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $47.05 | 2025 | Korlym |
| Mylan Specialty L.P. | $41.99 | 2024 | Yupelri |
| Lundbeck LLC | $34.62 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $29.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $27.12 | 2021 | |
| Lucid Diagnostics INC. | $26.10 | 2023 | |
| Edwards Lifesciences Corporation | $25.01 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sunovion Pharmaceuticals INC. | $20.39 | 2021 | |
| Cequr Corporation | $16.53 | 2025 | Cequr Simplicity |
| Amgen INC. | $14.44 | 2025 | Evenity |
| Aimmune Therapeutics, INC. | $14.17 | 2024 | |
| Janssen Pharmaceuticals, INC | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.